Pharma: Page 2
-
Mario Tama via Getty Images
Where Big Pharma’s campaign cash is flowing in this election
Big Pharma CEOs are hedging all bets by supporting both sides of the aisle in the 2024 election.
By Amy Baxter • Oct. 28, 2024 -
Stock via Getty Images
On the front lines of the superbug war, new treatments can’t arrive soon enough
As antimicrobial resistance rises, researchers are running out of time to fight each new wave of superbugs. And the funding isn’t enough.
By Kelly Bilodeau • Oct. 28, 2024 -
Explore the Trendline➔
Stock via Getty Images
TrendlineCommercialization, marketing and social media
As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.
By PharmaVoice staff -
Mario Tama via Getty Images
J&J’s comeback kid Spravato heads for blockbuster status
After a slow start, the novel esketamine nasal spray for depression is now J&J’s fastest-growing medication.
By Meagan Parrish • Oct. 25, 2024 -
Anton Vierietin / Getty Images via Getty Images
Why pharma megamergers may become a relic of the past
Despite pent up M&A demand, FTC scrutiny has had a chilling effect on pharma’s appetite for striking major deals.
By Kelly Bilodeau • Oct. 24, 2024 -
Buda Mendes via Getty Images
Dengue is spreading and Sanofi is pulling the U.S. market’s only vaccine. What’s next?
As Sanofi prepares to halt production on its dengue vaccine in 2026, locally acquired infections in the U.S. are raising the alarm.
By Alexandra Pecci • Oct. 23, 2024 -
George Clerk via Getty Images
With activist investment rising, Pfizer’s battle with Starboard reflects the industry’s post-pandemic tumble
Pfizer’s proxy battle with Starboard has gotten messy. It’s the latest in a series of activist investor campaigns that have been on the rise in recent years.
By Michael Gibney • Oct. 22, 2024 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Patient Champions
Leaders advancing health advocacy, DEI initiatives and better medicine access for patients.
By Meagan Parrish • Oct. 22, 2024 -
Douglas Cliff via Getty Images
FDA’s GLP-1 decision kicks off ‘unprecedented’ tussle over shortage
After initially declaring the shortage of Eli Lilly’s diabetes and weight loss drugs over, the FDA changed its mind and re-opened the door for GLP-1 compounders.
By Amy Baxter • Oct. 21, 2024 -
Monkey Business Images
Sponsored by CareMetxEmbedding into the provider’s workflow is key to a specialty drug’s success
Providers struggle with time-consuming processes. Patients are waiting for therapy. Embedded EMR system solutions can streamline therapy initiation and improve outcomes.
By Michael Sullivan, President of Provider Solutions at CareMetx • Oct. 21, 2024 -
PharmaVoice/PharmaVoice
PharmaVoice 1002024 PharmaVoice 100s: Cardiometabolic All-Stars
Leaders tackling long-standing health needs with new solutions.
By Amy Baxter • Oct. 18, 2024 -
Permission granted by Parexel
Clinical staff that feel like ‘tech support’ — and other issues a CRO exec contends with
From tech-related challenges to an ongoing staffing crunch, Parexel’s CEO explains what the clinical trials industry is up against.
By Meagan Parrish • Oct. 18, 2024 -
iStock via Getty Images
As new Alzheimer’s biomarkers come into play, here’s where the money is going
The Alzheimer’s Drug Discovery Foundation has its finger on the pulse of diagnostics to add precision to the next wave of therapies.
By Michael Gibney • Oct. 17, 2024 -
Christopher Furlong via Getty Images
Want to launch a blockbuster? An AstraZeneca exec breaks it down.
Even drugs with “blockbuster potential” often fall short of expectations. Here’s what can help a new medication pass the $1 billion mark.
By Alexandra Pecci • Oct. 16, 2024 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Trailblazers
Industry leaders charting new paths in science and business.
By Meagan Parrish • Oct. 16, 2024 -
Dan Kitwood/Getty Images via Getty Images
AlphaFold’s Nobel Prize is ‘the dawn of a new era’ in mapping drug development potential
A Nobel Prize in chemistry for Google’s DeepMind protein-structure mapping is the tip of the iceberg for advances in drug discovery and development.
By Michael Gibney • Oct. 15, 2024 -
Scott Olson via Getty Images
Drugmakers are racing to find the next Wegovy. These obesity trials are ones to watch.
Data readouts over the next six months could set expectations for how the highly lucrative market for weight loss therapies will look in the future.
By Jonathan Gardner • Oct. 15, 2024 -
Win McNamee via Getty Images
As election day nears, Trump and Harris veer in different directions on pharma
The two presidential candidates have developed diverging policies related to healthcare and pharma.
By Amy Baxter • Oct. 14, 2024 -
Permission granted by DeepWell
Will a Medicare boost propel digital therapeutics to the mainstream?
Digital therapeutics have languished in the background of traditional medicines for years, but a recent reimbursement push may have gotten the ball rolling.
By Kelly Bilodeau • Oct. 14, 2024 -
Photo illustration: Industry Dive; Getty Images
PharmaVoice 1002024 PharmaVoice 100s: Standout Leaders
Long-time executives with a strong track record of advancing drug R&D, business savvy strategies and leadership in various sectors of pharma.
By Meagan Parrish • Oct. 14, 2024 -
Stock via Getty Images
BMS’ next act for Cobenfy — and other highs and lows in Alzheimer’s
The Alzheimer’s space is booming, from a new use for a schizophrenia drug to discovered pathways linked to the disease — but there’s been stumbles too.
By Meagan Parrish • Oct. 11, 2024 -
Motortion via Getty Images
Regeneron takes the long-haul approach to oncology, stumbles and all
Although Regeneron has been playing catch-up in the oncology field for years, a pipeline built on next-wave promises could push the boundaries.
By Michael Gibney • Oct. 10, 2024 -
Courtesy of Madrigal
How Madrigal plans to win on the market with the first MASH drug
Despite the drug’s wide patient pool, Madrigal is taking a targeted approach with its first launch.
By Amy Baxter • Oct. 10, 2024 -
Permission granted by Katelyn Jetelina
Q&A‘It’s been hard to watch.’ A noted epidemiologist talks H5N1 and the U.S.’s fragmented response.
Katelyn Jetelina, well known for her newsletter “Your Local Epidemiologist,” digs into the H5N1 outbreak, the public health response and what’s next for vaccinations.
By Alexandra Pecci • Oct. 9, 2024 -
Stock via Getty Images
As AI transforms drug development, biotechs might not need as much Big Pharma support
Small biotechs are making gains with AI drug development, and their advantages may help some push ahead without Big Pharma.
By Amy Baxter • Oct. 9, 2024 -
Scott Olson via Getty Images
Novo’s GLP-1 Wegovy could improve heart health for millions more than previously thought, AI study finds
Through real-world data, an AI company found that popular weight loss drugs could be a preventive measure for patients at risk of heart attack and stroke.
By Kelly Bilodeau • Oct. 7, 2024
Previous
